Ultomiris Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The ultomiris market research report is one of a series of new reports that provides ultomiris market statistics, including ultomiris industry global market size, regional shares, competitors with ultomiris market share, detailed ultomiris market segments, market trends and opportunities, and any further data you may need to thrive in the ultomiris industry. This ultomiris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to increasing burden on healthcare systems, rising incidences of arthritis and inflammatory diseases, rising investments in research, increasing numbers of drug approvals, and increasing prevalence of musculoskeletal disorders. Major trends in the forecast period include advanced hospital infrastructure, advancement in treatment options, strategic research collaborations, development of orphan drugs, and expansion into new indications.

The increasing prevalence of autoimmune conditions is expected to drive the growth of the Ultomiris market. Autoimmune conditions occur when the immune system mistakenly targets and damages the body’s own cells and tissues. This rise in prevalence can be linked to environmental factors such as exposure to pollutants and chemicals, along with advancements in diagnostic methods that have led to more cases being identified and treated. Ultomiris is used to treat autoimmune diseases such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) by inhibiting complement protein C5, which helps reduce immune attacks on the body. For example, a report published by the Australian Institute of Health and Welfare in June 2024 highlighted a 25% increase in hospitalizations for rheumatoid arthritis, an autoimmune condition, from 8,000 in 2021 to 10,000 in 2022, with a hospitalization rate of 39 per 100,000 people. This growing prevalence of autoimmune diseases is contributing to the market expansion of Ultomiris.

Rising healthcare expenditure is anticipated to further boost the growth of the Ultomiris market. Healthcare expenditure refers to the financial resources allocated to medical services, infrastructure, insurance, and related sectors within a country or region. The increase in healthcare spending is driven by factors such as an aging population and the growing prevalence of chronic conditions, which result in higher long-term medical costs. Spending on Ultomiris includes the drug’s cost, its administration, patient monitoring, and ongoing research to expand its potential therapeutic uses. According to a report from the Office for National Statistics in May 2024, healthcare expenditure in the U.S. rose by 5.6% from 2022 to 2023, compared to just 0.9% growth in 2022. As healthcare spending continues to rise, it is expected to support the growth of the Ultomiris market.

A significant trend in the Ultomiris market is the expansion of its therapeutic indications through regulatory approvals. Regulatory approval involves the evaluation and authorization of a new drug by authorities to ensure its safety, efficacy, and quality. For instance, in March 2024, AstraZeneca received approval from the U.S. Food and Drug Administration (FDA) for Ultomiris (ravulizumab-cwvz) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for the anti-aquaporin-4 (AQP4) antibody. This marked a milestone as Ultomiris became the first long-acting C5 complement inhibitor approved for NMOSD, with clinical trials demonstrating a 98.6% reduction in relapse risk. Ultomiris works by inhibiting the complement system to prevent immune attacks on the central nervous system. However, it is associated with risks, including serious meningococcal infections and common side effects such as headaches and urinary tract infections.

The key company operating in the ultomiris market is AstraZeneca Plc.

North America was the largest region in the ultomiris market in 2024. The regions covered in ultomiris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ultomiris market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Ultomiris is a prescription medication containing the active ingredient ravulizumab-cwvz, a monoclonal antibody that targets and inhibits C5, a component of the immune system involved in the complement cascade. It is used to treat certain rare and severe autoimmune diseases by preventing the immune system from attacking healthy cells.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for Ultomiris include paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder in which red blood cells are prematurely destroyed, leading to hemolysis and blood clotting. Ultomiris is available in several formulations, including intravenous solutions and subcutaneous options, and is distributed through hospitals, clinics, and both retail and specialty pharmacies. It serves a variety of end users, including adult and pediatric patients.

The ultomiris market consists of sales of ultomiris injections, alpha-1 proteinase inhibitors, subcutaneous injections, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.